NCT04948333 2026-03-18
Asciminib Treatment Optimization in ≥ 3rd Line CML-CP
Novartis
Phase 3 Completed
Novartis
Repare Therapeutics
Suzhou Zanrong Pharma Limited
Guangzhou JOYO Pharma Co., Ltd
Merck Sharp & Dohme LLC
Bridge Biotherapeutics, Inc.
Shenzhen TargetRx Co., Ltd.